Ngm Biopharmaceuticals Stock Fundamentals
NGM Biopharmaceuticals fundamentals help investors to digest information that contributes to NGM Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of NGM Stock. The fundamental analysis module provides a way to measure NGM Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NGM Biopharmaceutica stock.
NGM |
NGM Biopharmaceuticals Company Return On Equity Analysis
NGM Biopharmaceutica's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current NGM Biopharmaceutica Return On Equity | -0.7 |
Most of NGM Biopharmaceutica's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NGM Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, NGM Biopharmaceuticals has a Return On Equity of -0.6976. This is 97.09% lower than that of the Pharmaceuticals sector and 98.09% lower than that of the Health Care industry. The return on equity for all United States stocks is 125.03% higher than that of the company.
NGM Biopharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining NGM Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare NGM Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NGM Biopharmaceutica competition to find correlations between indicators driving NGM Biopharmaceutica's intrinsic value. More Info.NGM Biopharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value NGM Biopharmaceutica by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NGM Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NGM Biopharmaceutica's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NGM Biopharmaceutica could also be used in its relative valuation, which is a method of valuing NGM Biopharmaceutica by comparing valuation metrics of similar companies.NGM Biopharmaceutica is currently under evaluation in return on equity category among its peers.
NGM Fundamentals
| Return On Equity | -0.7 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (179.78) % | |||
| Current Valuation | (36.13 M) | |||
| Shares Outstanding | 83.46 M | |||
| Shares Owned By Insiders | 21.08 % | |||
| Shares Owned By Institutions | 54.16 % | |||
| Number Of Shares Shorted | 1.68 M | |||
| Price To Earning | (21.12) X | |||
| Price To Book | 0.86 X | |||
| Price To Sales | 29.10 X | |||
| Revenue | 4.42 M | |||
| Gross Profit | (125.73 M) | |||
| EBITDA | (144.33 M) | |||
| Net Income | (142.38 M) | |||
| Cash And Equivalents | 297.81 M | |||
| Cash Per Share | 3.71 X | |||
| Total Debt | 5.38 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 7.49 X | |||
| Book Value Per Share | 1.79 X | |||
| Cash Flow From Operations | (132.2 M) | |||
| Short Ratio | 1.26 X | |||
| Earnings Per Share | (1.73) X | |||
| Target Price | 1.66 | |||
| Number Of Employees | 138 | |||
| Beta | 1.26 | |||
| Market Capitalization | 128.53 M | |||
| Total Asset | 168.87 M | |||
| Retained Earnings | (724.01 M) | |||
| Working Capital | 136.36 M | |||
| Current Asset | 330.81 M | |||
| Current Liabilities | 43.69 M | |||
| Net Asset | 168.87 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in NGM Stock
If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |